AstraZeneca's Tremelimumab/Imfinzi Combo Regime Goes Under Priority FDA Review For Liver Cancer

  • The FDA has accepted for review AstraZeneca Plc's AZN marketing application for tremelimumab as a single priming dose added to Imfinzi (durvalumab) for unresectable hepatocellular carcinoma (HCC). 
  • This novel dose and schedule of the combination is called the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab).
  • A supplemental marketing application has also been submitted for Imfinzi in this indication. 
  • Also Read: AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study.
  • Under priority review status, the Prescription Drug User Fee Act date is during Q2 of 2022.
  • The BLA for tremelimumab and sBLA for Imfinzi is based on final results from the HIMALAYA Phase 3 trial presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
  • In this trial, patients treated with the STRIDE regimen experienced a 22% reduction in the risk of death versus sorafenib.
  • Nearly one in three (31%) patients were still alive at three years versus one in five (20%) for sorafenib.
  • The safety profiles of the STRIDE regimen and for Imfinzi alone were consistent with the known profiles of each medicine, and no new safety signals were identified.
  • Price Action: AZN shares are down 1.78% at $64.69 during the premarket session on Monday's last check.

Posted In: BriefsBiotechLarge CapNewsHealth CareFDAMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.